Viral Vector Characterization and Analytical Development

In 2023, industry is witnessing a renaissance in viral vector characterization. Spurred by widespread biopharma investment to engineer a new wave of novel capsids and faced with newly launched QbD frameworks by US Pharmacopeia and the FDA’s tightened guidance, increased vector complexity is creating a new era for advanced analytical technologies to ensure precision and accuracy.

In the wake of significant collaborations including Vector Bio and iBET’s for high-throughput characterization, and the likes of Vertex and BMS announcing their priority to build out their internal analytical competencies, the inaugural Viral Vector Characterization & Analytical Development Summit arrives to pave the foundation for teams to further optimize process development and accelerate vector scale-up with GMP compliance in mind.

Uniting Characterization, Analytical, Formulation, Quality, Engineering, CMC and Process leaders, this industry-led summit is your only for cross-learning opportunities across AAV’s, LV’s & RV’s and more – so you can benchmark your work against rapid-analytical method development transforming your peers’ workflows, turnaround, and consistency.

Stay ahead of the curve, and join the likes of Ultragenyx, Kite Pharma, BioMarin, Neogene Therapeutics, Pfizer and many more for a 3-day jam packed agenda, set to tackle your biggest bottlenecks.